Peptide for visceral fat has only one evidence-backed option

Tesamorelin is the only peptide with phase 3 human trial proof that it reduces visceral fat, and it earned that record for a narrow reason that marketing copy tends to leave out. Almost every trial behind the number was run in people with HIV associated lipodystrophy, a specific fat redistribution syndrome, not in the general population trying to lose a stubborn midsection. Everything else sold today as a “peptide for visceral fat,” including AOD-9604 and the gray market GH secretagogues, is borrowing tesamorelin’s credibility without having trial data of its own. The honest version of this story is narrower than the hype, and that narrowness is worth understanding before anyone injects anything.

Bottom line: Tesamorelin is the one peptide with phase 3 trial proof that it shrinks visceral fat. That proof comes almost entirely from people with HIV associated lipodystrophy.

What the human trials found

Falutz and colleagues ran the pivotal study: 412 HIV patients with excess abdominal fat, 26 weeks, randomized, placebo controlled, double blind. Tesamorelin at 2 mg daily cut visceral adipose tissue by 15.2 percent, measured by CT scan, while the placebo group’s visceral fat rose 5.0 percent.^[1]

15.2% drop in visceral fat over 26 weeks on tesamorelin vs placebo PMID 18057338

That was not a one-off result. A follow-on extension kept part of the original cohort on tesamorelin for a full year. Visceral fat reduction held at 18 percent through 52 weeks of continuous treatment. When patients stopped taking the drug, the fat came back.^[2]

An earlier, smaller dose ranging study is worth a look too, because it shows how thin the evidence was before the phase 3 trials existed. In that 61 patient, 12 week study, visceral fat fell 15.7 percent at the 2 mg dose, numerically similar to the later phase 3 result. But split across three arms of roughly 20 patients each, the change did not clear statistical significance against placebo.^[3] It took the much larger phase 3 program to nail the effect down with confidence.

Here is the detail that gets lost in translation: most of the randomized controlled trial evidence for tesamorelin and visceral fat comes from people with HIV-associated lipodystrophy, not the general population trying to lose belly fat, as a 2026 meta-analysis pooling five of these trials confirms, finding consistent reductions in visceral fat, trunk fat and liver fat in a population that carried an HIV diagnosis in every trial.^[4] “Peptide for visceral fat” is a much bigger search term than “peptide for HIV associated fat redistribution,” and the gap between those two phrases is where most of the marketing confusion lives.

The mechanism: raising growth hormone, not melting fat directly

Tesamorelin is a synthetic analog of growth hormone releasing hormone. It does not touch fat cells directly. It pushes the pituitary gland to release growth hormone, which in turn raises insulin like growth factor 1, the hormone the drug is pharmacologically built around. In the same dose ranging trial above, IGF-1 rose 48 percent at the 1 mg dose and 65 percent at the 2 mg dose, both well past placebo.^[3]

That mechanism also explains an odd asymmetry in the data: visceral fat responds, subcutaneous fat mostly does not. A systematic review of ten randomized trials covering 1,511 patients with HIV associated lipodystrophy found growth hormone axis treatments, tesamorelin among them, reduced visceral fat by a weighted 25.2 square centimeters with no significant change in subcutaneous fat.^[5] The trial data draw that line clearly, even without fully explaining why one fat depot answers to growth hormone signaling and the other shrugs it off.

For a fuller rundown of the molecule itself, dosing history and approval status, see What Is Tesamorelin? A Straight Answer for Researchers.

The dose, and what we could not confirm about who it was tested on

Every trial behind this data used the same dose: 2 mg injected subcutaneously once a day. Tesamorelin is the only FDA-approved therapy for abdominal fat accumulation in HIV, and that approval rests on a phase 3 program run entirely at this dose.^[6]

What we could not verify from the published record is the exact exclusion criteria, such as whether people with poorly controlled diabetes or active cancer were kept out of these trials. That detail lives in trial protocols we could not confirm against a citable source, so this article will not guess at it. If that boundary matters to you, ask a clinician who can read the original protocol rather than take a secondhand summary on faith.

Side effects the trials recorded

Three safety patterns show up consistently across the tesamorelin literature:

• Injection site and growth hormone effects. A review of the HIV lipodystrophy trials found serious adverse events in under 4 percent of patients over 26 weeks. Most adverse events were injection site reactions or effects known to accompany growth hormone therapy, including joint pain, headache and swelling of the extremities.^[7]
• Glucose is watched, but the picture is mixed. In a 12-week trial of people with type 2 diabetes, tesamorelin did not significantly change fasting glucose, HbA1c or overall diabetes control compared with placebo, though trials in other populations have tracked glucose closely because tesamorelin raises IGF-1.^[8] That is a reassuring result in a population where you would expect trouble if it existed.
• Long-term cancer risk is simply unanswered. The longest published randomized data for tesamorelin runs to 52 weeks.^[2] A year of follow-up cannot establish or rule out cancer risk from sustained IGF-1 elevation, a question that by its nature needs a much longer observation window than any tesamorelin trial has run.

What the trials cannot tell you: whether 2 mg daily is safe or effective in someone without HIV, since only one small trial has ever tried.

Where tesamorelin stands against semaglutide and the gray-market peptides

Tesamorelin is not the only compound that moves visceral fat, and the comparison is instructive. GLP-1 receptor agonists such as semaglutide also reduce visceral fat, in one phase 3 trial by 40 percent at the highest dose, but as a secondary endpoint measured in a subset of participants within a broader weight-loss trial, unlike tesamorelin’s trials where visceral fat reduction was the primary endpoint.^[9] In that trial, the STEP 6 program, visceral fat area measured by CT fell 40.0 percent with semaglutide 2.4 mg at 68 weeks, versus 6.9 percent with placebo, but the trial was built to measure body weight, and visceral fat was a bonus number pulled from a subset scan. Different question, different kind of proof, and worth knowing if you are comparing the two compounds on the strength of their evidence rather than on a percentage pulled out of context.

The gray-market peptides sold for “spot” fat loss do not have either kind of proof. AOD-9604, a fragment of human growth hormone marketed for fat loss, falls into the lowest evidence tier in a 2026 review of GH-IGF-1 axis peptides: the tier with no regulatory-grade randomized trial data behind it, as opposed to tesamorelin, which has an FDA approval attached to its trial record.^[10] That same gap between marketing and trial record shows up across the peptide category. It is the same pattern documented in GHK-Cu Peptide Injection: The Human Evidence Gap, a different peptide sold on a different promise with the same absence of controlled human data behind it. For the broader pattern across the category, see Natural Peptides: Which Claims Have Human Trials.

Tesamorelin's randomized trial evidence

Visceral fat findings across the trials cited in this article.

What the evidence does not establish

Outside HIV, tesamorelin has been tested in only one randomized trial, 60 obese adults with reduced growth hormone secretion, not in the general population seeking to reduce visceral fat for metabolic health.^[11] It found the same selective pattern as the HIV trials: visceral fat dropped, subcutaneous fat did not move. That is one trial, in one narrow non-HIV subgroup. It is not evidence that tesamorelin works the same way in a healthy 35-year-old with no growth hormone deficiency and no HIV diagnosis.

Tesamorelin's effect does not outlast the prescription.

The discontinuation data reinforce the same limit from a different angle. Visceral fat regrowth after stopping tesamorelin is the headline finding of the extension study, and it means the drug works like a maintenance therapy that has to stay in use to keep its effect.^[2] Anyone treating this as a short course misunderstands what the trials tested.

Verdict: If a peptide claims to target visceral fat and it is not tesamorelin, ask what trial backs that claim. For most of them sold online today, the honest answer is none.

This article is for research and informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. The peptides discussed here are sold for research use only and are not for human consumption. Nothing in this article constitutes medical advice. Consult a qualified clinician before making changes to a health, training, or supplementation protocol.